Protagonist Therapeutics market cap PTGX
Share price times shares outstanding: what the whole company sells for, since 2016.
- Today, Nov 2, 2026
- $9B
- Highest close in our data
- $10B
- Aug 2026
Protagonist Therapeutics is worth $9B at the close on Nov 2, 2026, at $139.37 a share.
That is up 81% over the last year and up 460% over five years.
Its highest close in our data was $10B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $9B | $5B | $10B | +62% |
| 2025 | $5.6B | $2.2B | $6B | +139% |
| 2024 | $2.3B | $1.3B | $2.8B | +76% |
| 2023 | $1.3B | $573.7M | $1.7B | +146% |
| 2022 | $536.8M | $356.6M | $1.7B | −67% |
| 2021 | $1.6B | $790M | $2.3B | +112% |
| 2020 | $771.3M | $154.2M | $912.4M | +305% |
| 2019 | $190.4M | $167.9M | $408.9M | +24% |
| 2018 | $153.8M | $127.2M | $487.1M | −64% |
| 2017 | $426M | $138.6M | $426M | +16% |
| 2016 | $367.6M | $235.9M | $426.1M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| PTGXProtagonist Therapeutics | $9B |
| TGTXTG Therapeutics | $9.2B |
| CORTCorcept Therapeutics | $8.7B |
| ALKSAlkermes plc. | $7.5B |
| BMRNBiomarin Pharmaceutical | $11.1B |
| KNSAKiniksa Pharmaceuticals International | $7.1B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| LGNDLigand Pharmaceuticals | $6.1B |
| JAZZJazz Pharmaceuticals | $13.9B |
| INDVIndivior Pharmaceuticals | $4.3B |
| ARQTArcutis Biotherapeutics | $3.9B |
| Peer median | $7.3B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Protagonist Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.